Hers offers access to personalized weight loss plans without leaving your home
There might not be a one-size-fits-all approach to weight loss, but with personalized treatment plans and options from Hers, you can take control of your health and adopt a weight-loss strategy that's actually feasible for you.
Hers is an online platform that connects users with specialized healthcare services and providers that allow you to meet virtually, create a tailored weight loss plan and explore treatments that range from weight loss injections like compounded GLP-1s to meal replacement plans and oral medications for weight loss.
Whether you're looking to transform your health, improve your self-confidence or have direct access to a virtual provider to address your weight concerns, Hers can help get you started on the right track. To learn more, consider this your ultimate guide to Hers, with detailed information on weight loss treatments, costs and more, below:
What is Hers?
With a focus on women's healthcare, Hers is a telehealth platform that connects users with specialized healthcare services. Hers users are matched with a licensed medical care provider who can offer virtual consultations, as well as prescribe medication for select health concerns like mental health, sexual performance and weight loss.
What weight loss options does Hers offer?
The Weight Loss by Hers program is a holistic service that provides tools to help you better manage your weight, like nutrition support and meal replacement options, medical prescriptions (varies by provider), activity goals and more.
Weight loss treatment options include everything from prescription drugs such as Ozempic and Wegovy to compounded and branded GLP-1s.
How much does Hers cost?
Hers is designed to provide accessible health care at an affordable cost—no insurance necessary. Prices will vary depending on the subscription or treatment, and there is no membership fee. Personalized weight loss plans from Hers start at $69 per month, and compounded GLP-1s start at $199 per month.
Hers subscription benefits:
Hers can connect users to medical providers who specialize in a range of prescription treatment options depending on your needs. With a Hers subscription, you'll have access to virtual consultations with your healthcare provider (if they're available in you're state), 24/7 medical team support, personalized treatment plans and discreet at-home delivery of your prescriptions.
Our team of savvy editors independently handpicks all recommendations. If you purchase through our links, the USA Today Network may earn a commission. Prices were accurate at the time of publication but may change.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Viking Therapeutics Stock Zoomed 5% Higher Today
Key Points Positive news from a rival sparked a sympathy rally. This was aided by a positive research note published by an analyst. 10 stocks we like better than Viking Therapeutics › Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week. The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share price improve by more than 5% as a result. By contrast, the S&P 500 index basically traded flat across the trading session. What's good for the goose... The news driving Viking and other obesity drug developers came from a leading company in that space, Wegovy maker Novo Nordisk. Late Friday, the Denmark-based pharmaceutical announced that Wegovy earned approval from the U.S. Food and Drug Administration (FDA) to treat a new indication, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a liver disorder. Companies like Viking and Novo Nordisk have been on the radar of many of an investor because of the obvious side benefits to obesity drugs. The latter company earning a fresh approval to treat a medical issue besides obesity provides a significant morale boost to shareholders of weight loss drug developers. Bullish stance reiterated Also improving sentiment on Viking stock was that new analyst note. Monday morning before market open, Piper Sandler's Biren Amin reiterated his overweight (buy, in other words) recommendation and $71-per-share price target on the biotech. Amin's focus, according to reports, wasn't Novo Nordisk's recent news; rather, he was cheered by the prospects for VK2735. Viking is putting an oral version of the medication through clinical trials, and the readout of a phase 3 study is expected within this calendar quarter. In his estimation, if oral VK2735 continues to do well in testing and is brought to market, it could garner sales of $2.1 billion. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Why Viking Therapeutics Stock Zoomed 5% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Canada approves Ozempic to reduce risk of diabetic kidney disease progression
(Reuters) -Canada's health regulator has approved Novo Nordisk's diabetes drug, Ozempic, to reduce the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease, the Danish drugmaker said on Tuesday. The approval makes Novo's Ozempic, which belongs to the GLP-1 class of drugs, the first approved treatment in Canada to address type 2 diabetes as well as related kidney disease progression, the drugmaker said. The drug gained U.S. approval for the same indication earlier this year.
Yahoo
2 hours ago
- Yahoo
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
